Breaking Down Hainan Shuangcheng Pharmaceuticals Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Hainan Shuangcheng Pharmaceuticals is a turnaround story or a cautionary tale? Read on to see why investors are watching a company that posted CNY 168.9 million in sales for the nine months ending September 30, 2025-a 33% jump year‑over‑year from CNY 126.96 million-yet still reported full‑year 2024 revenue of CNY 174.21 million, down 26.16% from 2023 amid pressures from China's centralized drug procurement; the firm reported a 2024 net loss of CNY 42.99 million (EPS -CNY 0.10) and a nine‑month 2025 net loss improving to CNY 2.52 million (EPS -CNY 0.0061), while showing a troubling ROE of -27.04% and net profit margin of -48.84%; market signals add nuance-market cap stood at CNY 2.74 billion on December 18, 2025, with 414.69 million shares outstanding and a volatile 52‑week price range of CNY 6.32-21.77, yet a forward P/E of 18.69 and a conservative beta of 0.37 hint at investor expectations and lower market volatility; juxtapose these headwinds with potential upsides-entrusted revenue surged 244.96% in 2024, the company maintains a gross margin near 40%, invests over 10% of revenue in R&D and is pursuing international launches, out‑licensing and strategic partnerships-turn the page for a detailed breakdown of revenue drivers, profitability metrics, valuation, risks and growth prospects.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) - Revenue Analysis

• Nine months ended Sept 30, 2025 revenue: CNY 168.90 million (up 33% vs. CNY 126.96 million for same period prior year).
• Fiscal year 2024 revenue: CNY 174.21 million (down 26.16% vs. CNY 235.93 million in 2023).
• Entrusted revenue grew 244.96% in 2024, partially offsetting declines in core product sales.
• Primary cause of 2024 revenue decline: sustained price reductions from China's centralized drug procurement program (impacting pharmaceutical product ASPs since 2018).
• Market cap (Dec 18, 2025): CNY 2.74 billion - a 68.56% decrease year-over-year.
• 52-week stock price range: CNY 6.32-21.77, reflecting high investor uncertainty and volatility.

• Revenue composition shift: growing weight of entrusted services (244.96% increase in 2024) suggests management is diversifying away from price-pressured product sales.
• Short-term recovery signaled by 33% revenue growth in first nine months of 2025, but FY 2024 base remains materially lower than 2023.
• Investor sentiment is reflected in sharp market-cap compression and wide 52-week trading range, indicating elevated risk premia.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) Profitability Metrics

Recent reporting shows the company remains unprofitable but has narrowed losses year-over-year. Key headline figures and ratios highlight the scale of the challenge and the degree of improvement through September 30, 2025.

• Net loss (9M ending Sep 30, 2025): CNY 2.52 million (improved from CNY 37.84 million in 9M 2024).
• Basic & diluted loss per share from continuing operations (9M 2025): CNY 0.0061 vs. CNY 0.0913 (9M 2024).
• Net loss (FY 2024): CNY 42.99 million; EPS (2024): -CNY 0.10.
• Return on equity (ROE): -27.04% (indicating losses relative to shareholders' equity).
• Net profit margin: -48.84% (company is losing nearly half of revenue after expenses).

For context on strategy and corporate direction that may affect future profitability, see Mission Statement, Vision, & Core Values (2026) of Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) - Debt vs. Equity Structure

• Specific on-balance-sheet debt and equity breakdown: not readily available from the provided sources; detailed long-term/short-term debt figures and total shareholder equity are absent.
• Market capitalization (as of 2025-12-18): CNY 2.74 billion.
• Shares outstanding: 414.69 million.
• Stock price (2025-12-18): CNY 6.58 (down 0.30% vs. prior trading day).
• Beta: 0.37 (lower volatility relative to the broader market).
• Trailing P/E: not applicable due to negative earnings.
• Forward P/E: 18.69 (market-implied earnings improvement expected).

• Equity-centric snapshot: with market cap ≈ CNY 2.74bn and low beta, equity is priced for stability; forward P/E of 18.69 signals the market expects a recovery in profitability despite current negative trailing earnings.
• Leverage assessment constraints: without explicit total debt, net debt, or shareholders' equity figures, common leverage ratios (debt-to-equity, net-debt/EBITDA) cannot be reliably calculated from the available public summary.
• Practical implications for investors:
  • Conservative risk profile implied by beta 0.37, but profitability risk remains given negative trailing earnings.
  • Forward P/E suggests investors are pricing in operational improvement; confirm via upcoming earnings guidance and balance sheet disclosures.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) - Liquidity and Solvency

Available public data on Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) provides partial signals about market valuation, volatility and forward earnings expectations, while detailed balance-sheet liquidity and solvency ratios are not available in the cited sources.

• Detailed liquidity and solvency ratios (current ratio, quick ratio, interest coverage, debt-to-equity) are not provided in the available sources.
• Market capitalization (as of 2025-12-18): CNY 2.74 billion.
• Shares outstanding: 414.69 million.
• Stock price (2025-12-18): CNY 6.58 (down 0.30% vs prior day).
• Beta: 0.37 (lower volatility vs broader market).
• P/E: Not applicable due to negative trailing earnings.
• Forward P/E: 18.69 (market-implied expectation of earnings recovery).

• Interpretation cues for investors:
  • Low beta (0.37) implies stock price historically moves less than the market-relevant for portfolio volatility management.
  • Negative trailing earnings erase a meaningful trailing P/E; reliance shifts to forward estimates (forward P/E 18.69) and cash/solvency metrics (which are currently unavailable publicly).
  • Without published liquidity and solvency ratios, on-chain or audited balance-sheet review is recommended before making leverage-dependent investment decisions.

For additional company context including history, ownership and business model, see: Hainan Shuangcheng Pharmaceuticals Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) - Valuation Analysis

• Market-cap per share: implied market cap (CNY 2.74bn) divided by shares outstanding (414.69m) yields an implied per‑share value ≈ CNY 6.61, consistent with the 12/18/2025 close of CNY 6.58.
• Low beta (0.37) indicates the stock has historically exhibited substantially lower volatility than the broader market-useful for conservative allocation or risk-parity adjustments.
• Negative trailing earnings (P/E not applicable) and ROE at -27.04% signal current profitability weakness and capital impairment relative to equity; investors should examine recent net income drivers, one-off items, and balance-sheet impairments.
• Forward P/E of 18.69 implies market expectations of a return to positive earnings; assess the credibility of management guidance, pipeline milestones, or cost/restructuring plans that could drive that improvement.
• Price stability near implied per‑share market cap suggests limited near-term speculative premium; monitor trading volume and insider/major-holder activity for shifts in valuation sentiment.

For context on corporate direction and strategic priorities that may influence future valuation, see: Mission Statement, Vision, & Core Values (2026) of Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) - Risk Factors

• Revenue decline: reported a 26.16% decrease in 2024 vs. 2023, primarily attributed to the effects of China's centralized drug procurement program and downward pricing pressure across core product lines.
• Profitability deterioration: a net loss of CNY 42.99 million in 2024, signaling sustained operational and margin pressures.
• Negative margins and capital efficiency: ROE of -27.04% and a net profit margin of -48.84%, reflecting both equity erosion and deep operating losses.
• Market valuation volatility: 52-week stock price range of CNY 6.32-21.77, demonstrating substantial investor uncertainty and liquidity/valuation swings.
• Strategic execution risk: a planned acquisition was cancelled in March 2025 after negotiations failed, indicating difficulties in deal execution and inorganic growth plans.
• Regulatory risk: ongoing impact from China's centralized drug procurement policy (initiated significant price reductions since 2018) continues to compress revenue and margins across the sector.

• Investor implications:
  • Exposure to regulatory-driven price erosion-future centralized procurement rounds or extended price caps could further compress top-line and margins.
  • Balance-sheet and equity risk-negative ROE and retained losses may limit the company's ability to raise capital on favorable terms.
  • Operational and strategic risk-failed M&A attempts raise questions about management's ability to implement turnaround or growth strategies.
  • Market/liquidity risk-wide 52-week range implies potential for rapid mark-to-market losses for shareholders and sensitivity to news flow.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) Growth Opportunities

• Product portfolio expansion: the company now offers a diversified pipeline including thymalfasin, thymapentin, bortezomib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, exenatide, sodium ferulate injections, and vitamin B6 - enabling exposure across oncology, cardiovascular, metabolic and supportive-care segments.
• International market rollout: planned product launch activity in the Lecheng Free Trade Zone and expanded rollouts into Mainland China over the next 12 months, creating near-term market-access catalysts.
• Out-licensing and global expansion: active discussions around out-licensing of Maxigesic family medicines, Crystaderm, Capsaicin pain relieving cream, and Micolette microenema point to potential incremental royalty and licensing revenue streams.
• R&D intensity: R&D investment has exceeded 10% of annual revenue, underscoring a strategic emphasis on innovative biologics and novel formulations.
• Strategic distribution partnerships: collaborations with major U.S. pharmaceutical distributors and healthcare providers are being pursued to accelerate market penetration and strengthen supply-chain reach.
• Cost efficiency and pricing flexibility: a reported gross margin of ~40% supports competitive pricing while preserving profitability for reinvestment and marketing.

• Investor implications: the combined strategy - diversified product mix, committed R&D (>10% revenue), targeted international launches, and a 40% gross margin - creates multiple value levers (licensing income, new-market revenue, and margin expansion) while partnerships and out-licensing reduce commercialization risk and capital intensity.
• Key near-term catalysts to monitor: regulatory approvals in Lecheng FTZ, first product launches in Mainland China, execution of out-licensing deals for the Maxigesic family and other assets, and R&D pipeline readouts from prioritized programs.